AXA Framlington Biotech Z

Specialist biotech fund with a large exposure to US listed companies.

  • 152.60p
    Price (Inc)

    These are the shares in the fund that pay out an income to clients. The income is made up of the total dividends – the money a company can pay out to its investors – from the companies in the fund.

  • 444.40p
    Price (Acc)

    These are the shares in the fund that don’t pay out an income to clients. Any dividends – the money a company can pay out to its investors – are reinvested into companies in the fund. Despite no income, the shares should be worth more over time. Good incentive, eh?

  • 0.00%

    Initial charge

    Some funds charge you when you first invest, which is aptly known as the initial charge. They’re usually between 3-5% but at Bestinvest, we usually don’t charge you a penny!

  • 0.75%
    Annual management charge

    This is how much the fund management company charges to run the fund. It’s like paying a babysitter, dog sitter or house sitter (that makes well-informed, heavily researched changes to improve your baby/dog/house when needed).

  • 0.83%
    Ongoing charges

    This stands for Ongoing Charges Figure. It’s the cost of running a fund and includes admin fees, manager fees, administration costs, etc.

  • 0.00%

    How much the fund is currently paying out in income to investors. It’s NOT to be confused with the overall growth of a fund – a very different thing indeed. It’s also NOT a guarantee of future pay-outs, just a snapshot. This is more what it’s not than what it is…

Prices as at 07 May 2021

The fund targets long term capital appreciation by investing principally in the equity securities of companies in the biotechnology, genomic and medical research industries. The fund invests worldwide in companies of all sizes, but the bulk of the portfolio will consist of US stocks, reflecting the location of much of the biotech industry.

Fund summary

Sector Specialist
Structure UNIT TRUST
Launched April, 2012
Size £471m
Yield 0.00%
Charging basis Income
Dividends paid 30 Apr, 31 Oct


Standard initial charge 0.00%
Initial charge via Bestinvest 0.00%
Additional bid/offer spread 0.00%
Annual management charge 0.75%
Ongoing charges figure 0.83%


Proportion (%)

  • {{chartDataItem.text}}


Proportion (%)

  • {{chartDataItem.text}}


Proportion (%)

  • {{chartDataItem.text}}

Investment process

The fund’s investment universe consists of around 1000 public quoted biotech companies worldwide. These are filtered for such factors as ability to fund future operations and trading liquidity, reducing the universe to around 400-500 names which undergo qualitative analysis. Companies are assessed through contact with company management, attendance at conferences, consultation with industry experts and through consultation with other AXA Framlington fund managers. The manager targets companies with characteristics including: a strong product pipeline; quality management; robust clinical trial processes; market leading technologies. The process can also incorporate investment themes, such as the effects of the bird flu outbreak. Company sizes in the portfolio may be adjusted to reflect market conditions, with large, profitable companies favoured in more volatile environments.

Manager research

Average monthly relative returns

  • 16/17 -0.39%
  • 17/18 0.12%
  • 18/19 0.30%
  • 19/20 -0.18%
  • 20/21 -0.08%

Bestinvest MRI

  • 3 years 0.02%
  • 5 years -0.05%
  • Career -0.02%
  • 3 years 58.30%
  • 5 years 53.20%
  • Career 59.90%

Performance figures are based on the average of monthly percentage returns relative to the benchmark index.

Linden Thompson

Thompson joined the Healthcare team at AXA IM in June 2011. She started her career in 2004 at Goldman Sachs and spent five years as a healthcare analyst within the Global Investment Research division. Her coverage responsibility was the European biotechnology sector. She has since worked for the London-based, healthcare hedge fund, Clear River Capital. She was responsible for fundamental stock research across the global pharmaceutical and biotechnology sectors. Thompson holds a degree in Medical Microbiology from the University of Edinburgh.

Track record

Linden Thompson has 8.8 years experience of managing mutual funds in this sector. Over this period the average monthly return relative to the benchmark index has been -0.02%. During the worst period of relative performance (from October 2012 - November 2019) there was a decline of 14% relative to the index. The worst absolute loss has been 29%.

Periods of worst performance

Absolute -29.00% (July 2015 - March 2016)
Relative -14.00% (October 2012 - November 2019)

About the MRI

Our unique indicator: the Bestinvest Manager Record Index (MRI) measures the likelihood that the fund manager is adding value through their decisions. It is based on their performance record over the course of their career, adjusted for the amount of risk taken. MRI is an important contributor to our fund rating system but it is also vital to take account of qualitative factors. It is also very important to select funds to form a cohesive portfolio with an appropriate overall risk level.


Proportion (%)

  • {{chartDataItem.text}}


Proportion (%)

  • {{chartDataItem.text}}


Proportion (%)

  • {{chartDataItem.text}}

Top 10 holdings

Data accurate as at 31 July 2020

7.73% Regeneron Pharmaceuticals Inc
7.35% Amgen Inc
5.76% Biogen Inc
4.54% Vertex Pharmaceuticals Inc
4.46% Alexion Pharmaceuticals Inc
4.28% Gilead Sciences Inc
4.16% Seattle Genetics Inc
3.33% Incyte Corp
3.26% Biomarin Pharmaceutical
3.11% Illumina Inc
Source: Trustnet

Sector breakdown

Biotechnology/Medical 85.00%
Pharmaceuticals 6.00%
Technology 4.00%
Money Market 3.00%
Pharmaceuticals 1.00%


Approximately 100 stocks.


Minimum market cap £10m.

Key Investor Information - Income


Key Investor Information - Accumulation